RhoC a new target for therapeutic vaccination against metastatic cancer

L. Wenandy; R.B. Sorensen; P.T. Straten; M.H. Andersen; Inge Marie Svane

RhoC a new target for therapeutic vaccination against metastatic cancer

L. Wenandy, R.B. Sorensen, P.T. Straten, M.H. Andersen, Inge Marie Svane

17 Citationer (Scopus)

Abstract

Most cancer deaths are due to the development of metastases. Increased expression of RhoC is linked to enhanced metastatic potential in multiple cancers. Consequently, the RhoC protein is an attractive target for drug design. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of "therapeutic" vaccines. The over-expression of RhoC in cancer and the fact that immune escape by down regulation or loss of expression of this protein would reduce the morbidity and mortality of cancer makes RhoC a very attractive target for anti-cancer immunotherapy. Herein, we describe an HLA-A3 restricted epitope from RhoC, which is recognized by cytotoxic T cells. Moreover, RhoC-specific T cells show cytotoxic potential against HLA-matched cancer cells of different origin. Thus, RhoC may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies
Udgivelsesdato: 2008/12

Originalsprog	Engelsk
Tidsskrift	Cancer Immunology, Immunotherapy
Vol/bind	57
Udgave nummer	12
Sider (fra-til)	1871-1878
Antal sider	7
ISSN	0340-7004
Status	Udgivet - 2008

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

@article{4a98107087df11de8bc9000ea68e967b,

title = "RhoC a new target for therapeutic vaccination against metastatic cancer",

abstract = "Most cancer deaths are due to the development of metastases. Increased expression of RhoC is linked to enhanced metastatic potential in multiple cancers. Consequently, the RhoC protein is an attractive target for drug design. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of {"}therapeutic{"} vaccines. The over-expression of RhoC in cancer and the fact that immune escape by down regulation or loss of expression of this protein would reduce the morbidity and mortality of cancer makes RhoC a very attractive target for anti-cancer immunotherapy. Herein, we describe an HLA-A3 restricted epitope from RhoC, which is recognized by cytotoxic T cells. Moreover, RhoC-specific T cells show cytotoxic potential against HLA-matched cancer cells of different origin. Thus, RhoC may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies Udgivelsesdato: 2008/12",

author = "L. Wenandy and R.B. Sorensen and P.T. Straten and M.H. Andersen and Svane, {Inge Marie}",

note = "Times Cited: 0ArticleEnglishAndersen, M. HHerlev Univ Hosp, Dept Hematol, CCIT, DK-2730 Herlev, DenmarkCited References Count: 33351GISPRINGER233 SPRING ST, NEW YORK, NY 10013 USANEW YORK",

year = "2008",

language = "English",

volume = "57",

pages = "1871--1878",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer",

number = "12",

}

TY - JOUR

T1 - RhoC a new target for therapeutic vaccination against metastatic cancer

AU - Wenandy, L.

AU - Sorensen, R.B.

AU - Straten, P.T.

AU - Andersen, M.H.

AU - Svane, Inge Marie

N1 - Times Cited: 0ArticleEnglishAndersen, M. HHerlev Univ Hosp, Dept Hematol, CCIT, DK-2730 Herlev, DenmarkCited References Count: 33351GISPRINGER233 SPRING ST, NEW YORK, NY 10013 USANEW YORK

PY - 2008

Y1 - 2008

N2 - Most cancer deaths are due to the development of metastases. Increased expression of RhoC is linked to enhanced metastatic potential in multiple cancers. Consequently, the RhoC protein is an attractive target for drug design. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of "therapeutic" vaccines. The over-expression of RhoC in cancer and the fact that immune escape by down regulation or loss of expression of this protein would reduce the morbidity and mortality of cancer makes RhoC a very attractive target for anti-cancer immunotherapy. Herein, we describe an HLA-A3 restricted epitope from RhoC, which is recognized by cytotoxic T cells. Moreover, RhoC-specific T cells show cytotoxic potential against HLA-matched cancer cells of different origin. Thus, RhoC may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies Udgivelsesdato: 2008/12

AB - Most cancer deaths are due to the development of metastases. Increased expression of RhoC is linked to enhanced metastatic potential in multiple cancers. Consequently, the RhoC protein is an attractive target for drug design. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of "therapeutic" vaccines. The over-expression of RhoC in cancer and the fact that immune escape by down regulation or loss of expression of this protein would reduce the morbidity and mortality of cancer makes RhoC a very attractive target for anti-cancer immunotherapy. Herein, we describe an HLA-A3 restricted epitope from RhoC, which is recognized by cytotoxic T cells. Moreover, RhoC-specific T cells show cytotoxic potential against HLA-matched cancer cells of different origin. Thus, RhoC may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies Udgivelsesdato: 2008/12

M3 - Journal article

SN - 0340-7004

VL - 57

SP - 1871

EP - 1878

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 12

ER -